Working together to deliver cell and gene therapies for people impacted by serious diseases

Learn More

Our inspiration

Pipeline

EB-101

In Phase 3 development. Autologous gene-corrected cell therapy for patients with RDEB.

ABO-102

In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA).

ABO-50X

Exploring the potential of ABO-50X for the treatment of genetic eye disorders.

Manufacturing at The Elisa Linton Center for Rare Disease Therapies